Ascendis Pharma A (ASND) Gains from Investment Securities (2014 - 2026)

Ascendis Pharma A has disclosed Gains from Investment Securities across 13 years of filings, most recently posting $1.4 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $1.4 million, up 2589.26% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.2 million (down 8.31% YoY), and the FY2025 annual result was -$7.8 million, down 32.0% from the prior year.
• Gains from Investment Securities came in at $1.4 million for Q1 2026 at Ascendis Pharma A, up from -$431860.1 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $1.6 million in Q4 2022 to a low of -$4.6 million in Q2 2025.
• The 5-year median for Gains from Investment Securities is -$402778.5 (2023), against an average of -$959232.3.
• Across the five-year window, Gains from Investment Securities plunged 1378.1% in 2025 and jumped 2589.26% in 2026, its largest moves.
• Ascendis Pharma A's Gains from Investment Securities stood at $1.6 million in 2022, then tumbled by 314.34% to -$3.4 million in 2023, then jumped by 32.19% to -$2.3 million in 2024, then surged by 81.09% to -$431860.1 in 2025, then jumped by 415.28% to $1.4 million in 2026.
• The last three Gains from Investment Securities figures came in at $1.4 million (Q1 2026), -$431860.1 (Q4 2025), and -$2.5 million (Q3 2025), per Business Quant data.